Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Jane Street Group LLC

Jane Street Group LLC trimmed its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 79.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,437 shares of the biopharmaceutical company's stock after selling 132,994 shares during the period. Jane Street Group LLC owned approximately 0.05% of Xencor worth $814,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Barclays PLC boosted its stake in shares of Xencor by 100.7% during the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after buying an additional 78,066 shares during the last quarter. KBC Group NV raised its holdings in Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 813 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Xencor by 24.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company's stock valued at $341,000 after acquiring an additional 2,946 shares during the last quarter. Yousif Capital Management LLC grew its holdings in Xencor by 10.2% during the 4th quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company's stock worth $482,000 after acquiring an additional 1,944 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Xencor by 12.7% during the 4th quarter. State of Alaska Department of Revenue now owns 39,773 shares of the biopharmaceutical company's stock worth $913,000 after acquiring an additional 4,487 shares in the last quarter.

Analysts Set New Price Targets

XNCR has been the topic of a number of recent analyst reports. Wedbush restated an "outperform" rating and issued a $31.00 target price on shares of Xencor in a research note on Wednesday, April 30th. Wall Street Zen cut Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Barclays decreased their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research report on Thursday, May 8th. Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Finally, William Blair started coverage on shares of Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Two analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.50.

Xencor Stock Performance

Shares of NASDAQ XNCR traded up $0.18 during mid-day trading on Tuesday, hitting $7.75. The company had a trading volume of 1,491,798 shares, compared to its average volume of 657,047. Xencor, Inc. has a 12 month low of $7.16 and a 12 month high of $27.24. The stock has a market cap of $551.58 million, a price-to-earnings ratio of -2.42 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm's 50 day simple moving average is $9.56 and its two-hundred day simple moving average is $16.55.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. During the same period in the prior year, the business earned ($1.11) earnings per share. Xencor's quarterly revenue was up 104.6% on a year-over-year basis. As a group, equities research analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Insider Buying and Selling

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the transaction, the executive vice president now directly owns 49,169 shares of the company's stock, valued at $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.76% of the company's stock.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.